These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 20731658)

  • 1. Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?
    van Strien ME; Drukarch B; Bol JG; van der Valk P; van Horssen J; Gerritsen WH; Breve JJ; van Dam AM
    Brain Pathol; 2011 Jan; 21(1):44-54. PubMed ID: 20731658
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Astrocyte-derived tissue transglutaminase interacts with fibronectin: a role in astrocyte adhesion and migration?
    van Strien ME; Brevé JJ; Fratantoni S; Schreurs MW; Bol JG; Jongenelen CA; Drukarch B; van Dam AM
    PLoS One; 2011; 6(9):e25037. PubMed ID: 21949843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tissue transglutaminase in astrocytes is enhanced by inflammatory mediators and is involved in the formation of fibronectin fibril-like structures.
    Espitia Pinzón N; Brevé JJP; Bol JGJM; Drukarch B; Baron W; van Dam AM
    J Neuroinflammation; 2017 Dec; 14(1):260. PubMed ID: 29282083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tissue transglutaminase in marmoset experimental multiple sclerosis: discrepancy between white and grey matter.
    Espitia Pinzon N; Stroo E; 't Hart BA; Bol JG; Drukarch B; Bauer J; van Dam AM
    PLoS One; 2014; 9(6):e100574. PubMed ID: 24959868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tissue Transglutaminase contributes to experimental multiple sclerosis pathogenesis and clinical outcome by promoting macrophage migration.
    van Strien ME; de Vries HE; Chrobok NL; Bol JGJM; Breve JJP; van der Pol SMP; Kooij G; van Buul JD; Karpuj M; Steinman L; Wilhelmus MM; Sestito C; Drukarch B; Van Dam AM
    Brain Behav Immun; 2015 Nov; 50():141-154. PubMed ID: 26133787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Astrocyte-derived tissue Transglutaminase affects fibronectin deposition, but not aggregation, during cuprizone-induced demyelination.
    Espitia Pinzon N; Sanz-Morello B; Brevé JJ; Bol JG; Drukarch B; Bauer J; Baron W; van Dam AM
    Sci Rep; 2017 Jan; 7():40995. PubMed ID: 28128219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monocyte-derived tissue transglutaminase in multiple sclerosis patients: reflecting an anti-inflammatory status and function of the cells?
    Sestito C; Brevé JJP; van Eggermond MCJA; Killestein J; Teunissen CE; van Rossum J; Wilhelmus MMM; Drukarch B; van den Elsen PJ; van Dam AM
    J Neuroinflammation; 2017 Dec; 14(1):257. PubMed ID: 29268771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of Transglutaminase 2 activity inhibitors in monocytes in vitro and their effect in a mouse model for multiple sclerosis.
    Chrobok NL; Bol JGJM; Jongenelen CA; Brevé JJP; El Alaoui S; Wilhelmus MMM; Drukarch B; van Dam AM
    PLoS One; 2018; 13(4):e0196433. PubMed ID: 29689097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mapping the minimum domain of the fibronectin binding site on transglutaminase 2 (TG2) and its importance in mediating signaling, adhesion, and migration in TG2-expressing cells.
    Soluri MF; Boccafoschi F; Cotella D; Moro L; Forestieri G; Autiero I; Cavallo L; Oliva R; Griffin M; Wang Z; Santoro C; Sblattero D
    FASEB J; 2019 Feb; 33(2):2327-2342. PubMed ID: 30285580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tissue Transglutaminase Appears in Monocytes and Macrophages but Not in Lymphocytes in White Matter Multiple Sclerosis Lesions.
    Chrobok NL; Bol JGJM; Wilhelmus MMM; Drukarch B; van Dam AM
    J Neuropathol Exp Neurol; 2019 Jun; 78(6):492-500. PubMed ID: 31058279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.
    Monteagudo A; Ji C; Akbar A; Keillor JW; Johnson GVW
    Biochem Biophys Res Commun; 2017 Jan; 482(4):942-947. PubMed ID: 27899316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transglutaminase type 2 in human abdominal aortic aneurysm is a potential factor in the stabilization of extracellular matrix.
    Shin S; Cho YP; Jun H; Park H; Hong HN; Kwon TW
    J Vasc Surg; 2013 May; 57(5):1362-70. PubMed ID: 23538006
    [TBL] [Abstract][Full Text] [Related]  

  • 13. RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.
    Wang Z; Collighan RJ; Gross SR; Danen EH; Orend G; Telci D; Griffin M
    J Biol Chem; 2010 Dec; 285(51):40212-29. PubMed ID: 20929862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Depletion of astrocytic transglutaminase 2 improves injury outcomes.
    Monteagudo A; Feola J; Natola H; Ji C; Pröschel C; Johnson GVW
    Mol Cell Neurosci; 2018 Oct; 92():128-136. PubMed ID: 29969654
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Transglutaminase 2 strongly binds to an extracellular matrix component other than fibronectin via its second C-terminal beta-barrel domain.
    Stamnaes J; Cardoso I; Iversen R; Sollid LM
    FEBS J; 2016 Nov; 283(21):3994-4010. PubMed ID: 27685605
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of tissue transglutaminase (TG2) in regulating the tumour progression of the mouse colon carcinoma CT26.
    Kotsakis P; Wang Z; Collighan RJ; Griffin M
    Amino Acids; 2011 Oct; 41(4):909-21. PubMed ID: 21046178
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small molecule inhibitors target the tissue transglutaminase and fibronectin interaction.
    Yakubov B; Chen L; Belkin AM; Zhang S; Chelladurai B; Zhang ZY; Matei D
    PLoS One; 2014; 9(2):e89285. PubMed ID: 24586660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tissue Transglutaminase contributes to myelin phagocytosis in interleukin-4-treated human monocyte-derived macrophages.
    Sestito C; Brevé JJP; Bol JGJM; Wilhelmus MMM; Drukarch B; van Dam AM
    Cytokine; 2020 Apr; 128():155024. PubMed ID: 32032932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transglutaminase 2 inhibitor, KCC009, disrupts fibronectin assembly in the extracellular matrix and sensitizes orthotopic glioblastomas to chemotherapy.
    Yuan L; Siegel M; Choi K; Khosla C; Miller CR; Jackson EN; Piwnica-Worms D; Rich KM
    Oncogene; 2007 Apr; 26(18):2563-73. PubMed ID: 17099729
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transglutaminase-2 interaction with heparin: identification of a heparin binding site that regulates cell adhesion to fibronectin-transglutaminase-2 matrix.
    Lortat-Jacob H; Burhan I; Scarpellini A; Thomas A; Imberty A; Vivès RR; Johnson T; Gutierrez A; Verderio EA
    J Biol Chem; 2012 May; 287(22):18005-17. PubMed ID: 22442151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.